Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 3.16 Million USD | -10.29% |
| 2021 | 3.52 Million USD | 73.88% |
| 2020 | 2.02 Million USD | 4567.32% |
| 2019 | -45.44 Thousand USD | 65.42% |
| 2018 | -131.4 Thousand USD | 85.07% |
| 2017 | -880.24 Thousand USD | 57.22% |
| 2016 | -2.05 Million USD | -53720.25% |
| 2015 | -3823.00 USD | 99.17% |
| 2014 | -459.58 Thousand USD | -71597.82% |
| 2013 | -641.00 USD | -462.28% |
| 2012 | -114.00 USD | -714.29% |
| 2011 | -14.00 USD | 6.67% |
| 2010 | -15.00 USD | 99.92% |
| 2009 | -18.6 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | 2.84 Million USD | 5.35% |
| 2022 Q1 | 2.7 Million USD | -23.47% |
| 2022 FY | 3.16 Million USD | -10.29% |
| 2022 Q4 | 3.16 Million USD | 6.33% |
| 2022 Q3 | 2.97 Million USD | 4.65% |
| 2021 Q3 | 3.13 Million USD | 35.17% |
| 2021 Q2 | 2.32 Million USD | 4.36% |
| 2021 Q1 | 2.22 Million USD | 9.59% |
| 2021 FY | 3.52 Million USD | 73.88% |
| 2021 Q4 | 3.52 Million USD | 12.48% |
| 2020 Q3 | 703.63 Thousand USD | 217.21% |
| 2020 Q2 | 221.81 Thousand USD | 2182.2% |
| 2020 Q1 | -10.65 Thousand USD | 76.56% |
| 2020 FY | 2.02 Million USD | 4567.32% |
| 2020 Q4 | 2.02 Million USD | 188.5% |
| 2019 Q1 | -7327.00 USD | 94.42% |
| 2019 Q2 | -344.97 Thousand USD | -4608.31% |
| 2019 FY | -45.44 Thousand USD | 65.42% |
| 2019 Q3 | -218.16 Thousand USD | 36.76% |
| 2019 Q4 | -45.44 Thousand USD | 79.17% |
| 2018 Q1 | -666.84 Thousand USD | 24.24% |
| 2018 Q2 | -430.93 Thousand USD | 35.38% |
| 2018 FY | -131.4 Thousand USD | 85.07% |
| 2018 Q4 | -131.4 Thousand USD | 52.81% |
| 2018 Q3 | -278.47 Thousand USD | 35.38% |
| 2017 Q4 | -880.24 Thousand USD | -39.49% |
| 2017 Q2 | -91.73 Thousand USD | 62.37% |
| 2017 Q3 | -631.05 Thousand USD | -587.89% |
| 2017 Q1 | -243.76 Thousand USD | 88.15% |
| 2017 FY | -880.24 Thousand USD | 57.22% |
| 2016 Q4 | -2.05 Million USD | -123.82% |
| 2016 FY | -2.05 Million USD | -53720.25% |
| 2016 Q3 | -919.29 Thousand USD | -219.94% |
| 2016 Q2 | -287.33 Thousand USD | 12.18% |
| 2016 Q1 | -327.18 Thousand USD | -8458.2% |
| 2015 Q3 | - USD | 100.0% |
| 2015 FY | -3823.00 USD | 99.17% |
| 2015 Q4 | -3823.00 USD | 0.0% |
| 2015 Q1 | -280.65 Thousand USD | 38.93% |
| 2015 Q2 | -175.11 Thousand USD | 37.61% |
| 2014 Q2 | -631.00 USD | -33.97% |
| 2014 FY | -459.58 Thousand USD | -71597.82% |
| 2014 Q4 | -459.58 Thousand USD | -2297815.0% |
| 2014 Q1 | -471.00 USD | 26.52% |
| 2014 Q3 | -20.00 USD | 96.83% |
| 2013 Q2 | -748.00 USD | -740.45% |
| 2013 FY | -641.00 USD | -462.28% |
| 2013 Q4 | -641.00 USD | -24.22% |
| 2013 Q3 | -516.00 USD | 31.02% |
| 2013 Q1 | -89.00 USD | 21.93% |
| 2012 FY | -114.00 USD | -714.29% |
| 2012 Q2 | -14.00 USD | 53.33% |
| 2012 Q1 | -30.00 USD | -114.29% |
| 2012 Q3 | -71.00 USD | -407.14% |
| 2012 Q4 | -114.00 USD | -60.56% |
| 2011 Q1 | -56.00 USD | -273.33% |
| 2011 FY | -14.00 USD | 6.67% |
| 2011 Q4 | -14.00 USD | -600.0% |
| 2011 Q3 | -2.00 USD | 92.31% |
| 2011 Q2 | -26.00 USD | 53.57% |
| 2010 Q4 | -15.00 USD | 99.73% |
| 2010 FY | -15.00 USD | 99.92% |
| 2010 Q3 | -5649.00 USD | 0.0% |
| 2009 Q4 | -18.6 Thousand USD | 0.0% |
| 2009 FY | -18.6 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -74.365% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 183.006% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -152.526% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 90.17% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 437.24% |
| Better Therapeutics, Inc. | -860 Thousand USD | 468.219% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 113.314% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -864.155% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 30.707% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 154.382% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 0.979% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 36.692% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 97.638% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -1667.614% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 74.335% |
| Molecular Templates, Inc. | 707 Thousand USD | -347.904% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -622.254% |
| NexImmune, Inc. | -3.13 Million USD | 201.054% |
| Orgenesis Inc. | 21.78 Million USD | 85.463% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -21.05% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 635979.719% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 167.224% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 2641.988% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 97.144% |
| Statera Biopharma, Inc. | 14.41 Million USD | 78.034% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 141.689% |
| Trevena, Inc. | 2.25 Million USD | -40.243% |
| Vaxxinity, Inc. | 10.13 Million USD | 68.746% |
| Vaccinex, Inc. | -1.28 Million USD | 345.86% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -819.355% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 76.081% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -4300.491% |